My Personal CFO LLC’s DexCom DXCM Stock Holding History

My Personal CFO LLC’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$679	–	279
2022 Q4	$679	Buy	+6	New	+$659	﹤0.01%	701

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

My Personal CFO LLC's DXCM Position: Q1 2023 in Review

My Personal CFO LLC sold out of DexCom (DXCM) in Q1 2023, closing a stake of 6 shares — an estimated $679 sold.

My Personal CFO LLC first reported a position in DXCM in Q4 2022 and held it in 1 quarter. The position peaked at $679 in Q4 2022. 904 funds tracked by Wall St. Rank hold DXCM as of Q1 2023.

My Personal CFO LLC reported no remaining DexCom position as of Q1 2023 after selling out during the quarter.
My Personal CFO LLC sold 6 DexCom shares in Q1 2023, an estimated $679.
My Personal CFO LLC first reported a position in DexCom in Q4 2022 and held it in 1 quarter.
My Personal CFO LLC's DexCom position peaked at $679 in Q4 2022.
904 funds tracked by Wall St. Rank held DexCom as of Q1 2023.

Based on My Personal CFO LLC's 13F filing for Q1 2023, filed 21 Apr 2023.